Insider Trading Arrangements

3 Months Ended

Mar. 31, 2026

Our policy governing transactions in our securities by our directors, officers and employees permits our directors, officers and employees to enter into trading plans complying with Rule 10b5-1 under the Exchange Act. The following table describes the written plans for the sale of our securities that were adopted by our executive officers and directors during the quarter ended March 31, 2026. Each plan was entered into during an open trading window and is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) (each a “Trading Plan”).

Name and Title

Action Taken (Date)

Scheduled Start Date of Trading Plan

Scheduled Expiration Date of Trading Plan

Maximum Number of Shares Subject to Trading Plan

Richard Levy, M.D., Director

Modification (February 20, 2026)

5/22/2026

12/31/2026

5,682

David Soergel, M.D., Chief Medical Officer

Adoption (March 02, 2026)

6/1/2026

12/31/2026

4,2931

(1) This Trading Plan provides for the sale of shares to be received upon future vesting of certain outstanding restricted stock unit awards, net of any shares sold to satisfy applicable taxes. The number of shares to be sold to satisfy taxes, and thus the exact number of shares to be sold pursuant to this Trading Plan, can only be determined upon the occurrence of future vesting events. For purposes of this disclosure, we have reported the maximum aggregate number of shares to be sold without subtracting any shares to be sold to satisfy tax obligations.

Non-Rule 10b5-1 Arrangement Adopted

false

Rule 10b5-1 Arrangement Terminated

false

Non-Rule 10b5-1 Arrangement Terminated

false

Richard Levy, M.D [Member]

Trading Arrangements, by Individual

Name

Richard Levy, M.D.

Title

Director